The Huang lab research focuses on translational pharmacogenomic with particular interest in the pharmacogenomics of anticancer agents. By systematically evaluating the human genomes and their relationships to drug response and toxicity, our goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. We conduct research through cutting edge computational and experimental methods. Utilizing cell lines (derived from healthy and disease individuals as well as commercially available cancer cell lines), and clinical samples, we discover and functionally characterize genetic variations, gene and non-coding RNA (i.e., microRNA, lncRNA) expression for their role in chemotherapeutic sensitivity.
